Tolaney S, et al. MonarcHER: a randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of care chemotherapy in women with HR+, HER2+ advanced breast cancer. Abstract LBA23. ESMO Congress 2019, 29 sept. Barcelona, Spanje.
Adjuvant sorafenib na RFA verbetert prognose van HCC-patiënten
aug 2022 | Maag-darm-leveroncologie